Overview
New York, NY – July 24, 2026 – The Global Genetic Testing Market size is expected to be worth around US$ 100.63 billion by 2034 from US$ 13.89 billion in 2024, growing at a CAGR of 21.9% during the forecast period 2025 to 2034. North America held a dominant market position, capturing more than a 43.8% share and holding a US$ 6.08 billion market value for the year.
The genetic testing market is witnessing strong growth driven by rapid advancements in genomics, biotechnology, and personalized healthcare. Genetic testing involves analyzing DNA, blood, or tissue samples to identify genetic variations linked to inherited disorders, disease risks, and treatment responses. These tests play an important role in early diagnosis, preventive healthcare, precision medicine, cancer screening, and family planning decisions.
The increasing adoption of Next-Generation Sequencing (NGS) technologies has significantly improved the accuracy, speed, and affordability of genetic tests, making them more accessible to healthcare providers and consumers. Genetic testing is widely used in oncology, prenatal screening, rare disease diagnosis, pharmacogenomics, and ancestry research. The growing demand for targeted therapies and personalized treatment approaches is further supporting market expansion.
In March 2023, Illumina Inc. expanded its strategic partnership with Myriad Genetics Inc. to improve access to oncology homologous recombination deficiency (HRD) testing in the United States through the availability of Illumina TruSight Oncology 500 HRD. Additionally, in May 2025, Gene Solutions partnered with NEWCL Biomedical Laboratory to establish an advanced Next-Generation Sequencing laboratory in Taiwan, strengthening regional genetic testing capabilities.
Despite challenges related to genetic data privacy, ethical concerns, and regulatory compliance, increasing healthcare awareness, rising adoption of precision medicine, and expanding applications in disease prevention are expected to create significant growth opportunities for the genetic testing market in the coming years.
Key Takeaways
- In 2024, the Genetic Testing Market generated revenue of US$ 13.89 billion and is projected to grow at a CAGR of 21.9%, reaching approximately US$ 100.63 billion by 2034.
- Based on Product, the market is segmented into Consumables, Software & Services, and Equipment, with Consumables leading the segment in 2024 with a 46.8% market share.
- By Technology, the market includes Next-Generation Sequencing (NGS), Array Technology, PCR-based Testing, FISH, Microarray, and Others, with Next-Generation Sequencing dominating in 2024 with a 39.6% market share.
- By Test Type, the market is categorized into Diagnostic Testing, Predictive & Pre-symptomatic Testing, Carrier Testing, Prenatal & Newborn Testing, and Pharmacogenomic Testing, with Diagnostic Testing accounting for the largest share at 59.7% in 2024.
- Based on Application, the market is segmented into Oncology, Neurology, Cardiology, Rare Diseases, Reproductive Health, and Others, with Oncology leading the market with a 36.8% share in 2024.
- By End User, the market is divided into Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others, with Hospitals & Clinics holding the dominant position with a 43.9% market share in 2024.
- North America dominated the Genetic Testing Market in 2024, accounting for a 43.8% market share due to advanced healthcare infrastructure, increasing adoption of precision medicine, and strong genomic research activities.
Statistical Information
- Availability and Growth of Genetic Tests: As of April 2023, the U.S. National Institutes of Health (NIH) Genetic Testing Registry (GTR) listed 76,326 unique genetic tests, covering 5,452 conditions and 5,407 genes, reflecting the rapid expansion of available tests over the past decade.
- Consumer Awareness and Use of Genetic Testing: An analysis of the U.S. National Cancer Institute’s Health Information National Trends Survey (HINTS 5, Cycle 3 and 4), which is a federally funded, nationally representative survey, found that 75% of participants were aware of genetic testing and 19% had undergone some form of genetic testing as of 2017–2018.
- Detailed Awareness and Uptake in 2022: A 2022 survey of 6,252 U.S. adults reported that 81.4% were aware of genetic testing and 40.0% had undergone at least one type of genetic test, indicating substantial diffusion of these services.
- Direct‑to‑Consumer Genetic Testing Scale: The U.S. National Human Genome Research Institute (NHGRI), part of NIH, reports that by 2018 more than 26 million consumers had contributed their DNA to commercial genetic testing databases, primarily through DTC ancestry and health testing services.
- Regulatory Perspective on Direct‑to‑Consumer Tests: The FDA defines direct‑to‑consumer tests as in vitro diagnostics marketed directly to consumers without the involvement of a health care provider, and it distinguishes categories such as genetic health risk tests, carrier screening tests, and pharmacogenomic tests.
- Spending and Test Volume in the U.S. Health System: A study using a large U.S. payer genetic testing claims database found that there were approximately 75,000 distinct genetic tests on the U.S. market by the mid‑2010s, with around ten new tests entering the market each day during the study period.
- Diagnostic Testing Market Context: The same source estimated that the U.S. diagnostic testing market would reach 40.1 billion USD by 2026, representing around 25% of the global diagnostic market value, indicating the scale of testing infrastructure where genetic testing is a rapidly growing component.
Regional Analysis
North America dominated the Genetic Testing Market in 2024, accounting for a 43.8% market share
North America remains a leading region in genetic testing adoption due to advanced healthcare infrastructure, strong genomic research capabilities, and increasing integration of precision medicine into clinical practice. The region has witnessed growing use of next-generation sequencing (NGS), whole genome sequencing, and molecular diagnostic technologies for cancer detection, rare disease diagnosis, prenatal screening, and personalized treatment decisions.
Genetic testing enables healthcare providers to identify DNA changes linked with inherited conditions and guide medical management. The United States has strengthened genomic healthcare through large-scale initiatives such as the NIH All of Us Research Program, which supports precision medicine research using diverse health and genomic data.
Increasing adoption of genomic testing in pediatric care is also supporting market growth. In 2025, the American Academy of Pediatrics recommended exome and genome sequencing as first-tier tests for many children with global developmental delay or intellectual disability due to improved diagnostic yield and cost-effectiveness. These advancements continue to expand genetic testing applications across oncology, rare diseases, and personalized healthcare in North America.
Emerging Trends
- Expansion of Next-Generation Sequencing (NGS) in Clinical Diagnosis: Next-generation sequencing is becoming a key trend in genetic testing due to its ability to analyze millions of DNA sequences quickly. FDA recognises NGS-based technologies as important tools for identifying genetic variants, supporting disease diagnosis, treatment selection, and precision medicine applications.
- Growing Adoption of Pharmacogenomic Testing: Pharmacogenomics is gaining importance as healthcare providers use genetic information to understand patient responses to medications. NIH highlights that genetic-based drug response testing helps identify suitable treatments and improve medication safety. FDA includes pharmacogenomic information in drug labels for several therapies.
- Increasing Genetic Testing for Rare Disease Diagnosis: Genetic testing is improving the diagnosis of rare diseases by identifying inherited genetic changes that are difficult to detect through traditional methods. NIH estimates that approximately 25–30 million Americans live with rare diseases, increasing demand for advanced genomic testing solutions.
- Integration of Artificial Intelligence (AI) in Genomic Analysis: AI-based tools are increasingly being used to analyze complex genomic datasets and identify disease-related genetic patterns. NIH-supported research focuses on artificial intelligence applications that improve interpretation of sequencing results, mutation identification, and clinical decision-making.
- Growth of Precision Oncology and Cancer Genomics: Cancer genomic testing is expanding as healthcare providers use molecular information to identify tumor characteristics and select targeted therapies. NIH precision medicine programs support genomic approaches that divide cancers into specific molecular subtypes for personalized treatment strategies.
Use Cases
- Early Detection and Genetic Risk Assessment: Genetic testing helps identify inherited conditions, disease risks, and genetic mutations before symptoms appear. CDC states that genetic tests can support diagnosis, evaluate inherited disease risks, and help healthcare professionals develop personalized prevention and treatment plans.
- Prenatal and Newborn Genetic Screening: Genetic testing is widely used in prenatal and newborn healthcare to detect inherited disorders at early stages. These tests help families and physicians identify potential health conditions and support early medical interventions for affected infants.
- Personalized Medicine Through Pharmacogenomics: Pharmacogenomic testing helps determine how an individual’s genes affect their response to medicines. CDC highlights that this approach can support safer prescribing decisions by helping healthcare providers select suitable drugs and reduce possible adverse reactions.
- Genome Sequencing for Pediatric Disorders: Whole exome sequencing and whole genome sequencing are increasingly used for children with developmental delays and intellectual disabilities. Updated clinical recommendations support these tests as first-tier options because they improve diagnostic accuracy and enable earlier treatment planning.
- Direct-to-Consumer (DTC) Genetic Testing: Consumer genetic testing services allow individuals to access information related to ancestry, inherited traits, and potential health risks through saliva or DNA samples. CDC highlights that genetic testing results can provide valuable insights when combined with professional genetic counseling.
Frequently Asked Questions on Genetic Testing Market
- Why is genetic testing important in healthcare?
Genetic testing helps healthcare professionals understand disease causes, identify inherited risks, and select suitable treatments. It supports early diagnosis, personalized medicine, cancer management, reproductive planning, and preventive healthcare by providing detailed information about an individual’s genetic profile. - What are the major applications of the Genetic Testing Market?
The genetic testing market is used in oncology, rare disease diagnosis, prenatal screening, newborn testing, pharmacogenomics, and personalized medicine. These applications help detect genetic abnormalities, understand disease progression, and improve treatment outcomes through targeted healthcare approaches. - How does Next-Generation Sequencing (NGS) impact genetic testing?
Next-generation sequencing has transformed genetic testing by enabling rapid analysis of large DNA sequences with improved accuracy. NGS supports disease identification, cancer profiling, rare disease diagnosis, and precision medicine by providing comprehensive genetic information for clinical decision-making. - What factors are driving the growth of the Genetic Testing Market?
The genetic testing market is growing due to increasing demand for personalized medicine, rising awareness of genetic disorders, advancements in sequencing technologies, and expanding applications in oncology and rare disease diagnosis. Improved accessibility and reduced testing costs are also supporting adoption. - How is pharmacogenomics used in genetic testing?
Pharmacogenomic testing analyzes genetic variations that influence how individuals respond to medications. It helps healthcare providers select appropriate drugs and dosages, reduce adverse reactions, and improve treatment effectiveness, supporting safer and more personalized healthcare decisions. - Who are the key users of genetic testing services?
Genetic testing services are widely used by hospitals, diagnostic laboratories, research institutions, physicians, and consumers. Healthcare providers use these tests for diagnosis and treatment planning, while individuals use them for health risk assessment, ancestry information, and family planning decisions.
Conclusion
The genetic testing market is experiencing significant transformation due to advancements in genomics, next-generation sequencing, and personalized medicine. Increasing adoption in oncology, rare disease diagnosis, prenatal screening, and pharmacogenomics is improving disease detection and treatment strategies. North America continues to lead due to strong healthcare infrastructure, genomic research initiatives, and growing clinical applications.
Emerging technologies such as artificial intelligence and genome sequencing are further enhancing testing accuracy and accessibility. Despite challenges related to privacy, ethical concerns, and data security, expanding healthcare applications and increasing awareness of genetic-based solutions are expected to support continued growth and innovation in the genetic testing market.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
